Bharat Biotech units up CRDMO arm to give attention to cell and gene therapies

Vaccine maker Bharat Biotech has established a contract analysis growth and manufacturing organisation (CRDMO) centered on cell and gene therapies.

Setting up of the wholly-owned subsidiary Nucelion Therapeutics is a part of a strategic enlargement into the fast-growing area of next-generation cell and gene remedy CRDMO. It goals to assist world life science innovators with high-quality, scalable course of growth and manufacturing options for superior therapies, indicated for cancers, autoimmune issues and uncommon genetic issues, Bharat Biotech mentioned asserting the formal launch of the arm on Monday (November 3, 2025).

Nucelion Therapeutics to supply end-to-end companies

Spread throughout a 30,000 sq ft purpose-built facility in Genome Valley, Hyderabad, Nucelion has commissioned a GMP facility able to creating and manufacturing plasmids, viral and non-viral vectors, cell therapies, and aseptic fill and end, offering end-to-end companies for shoppers. The firm will supply end-to-end companies, from early-stage scientific growth to commercial-scale manufacturing, whereas adhering to worldwide regulatory requirements, together with these of the FDA and EMA, it mentioned.

“The way forward for pharmaceutical innovation can be organic. CGTs are a key vector. Our imaginative and prescient is to combine superior remedy platforms into India’s healthcare ecosystem, enabling equitable options for advanced and uncommon ailments,” Bharat Biotech founder and non-executive director of Nucelion Therapeutics Krishna Ella mentioned.

Firm hiring scientific, operational expertise

Cell therapies — autologous, allogeneic, and rising in vivo approaches — are poised to maneuver from area of interest packages to scalable platforms, increasing from uncommon ailments into broader oncology, immunology, and regenerative care as manufacturing, analytics, and supply applied sciences mature. Nucelion will function with impartial management, governance, and knowledge techniques, and interact all sponsors, together with Bharat Biotech, on arm’s-length industrial phrases. The firm is hiring scientific and operational expertise with world expertise in cell and gene remedy execution.

“We will present end-to-end options from scientific to industrial scale, making certain regulatory compliance with world requirements. The firm affords companies for growth and manufacturing of plasmid DNA, viral vectors, autologous and allogeneic cell therapies,” chief enterprise officer of Nucelion Therapeutics Raghu Malapaka mentioned in a launch.